Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates

Journal of Cellular Biochemistry

Volumn 112, Issue 6, 2011, Pages 1593-1600

  Thiele, Sylvia ^a   Rauner, Martina ^a   Goettsch, Claudia ^a   Rachner, Tilman D ^a   Benad, Peggy ^a   Fuessel, Susanne ^b   Erdmann, Kati ^b   Hamann, Christine ^b   Baretton, Gustavo B ^b   Wirth, Manfred P ^b   Jakob, Franz ^c   Hofbauer, Lorenz C ^a,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

bisphosphonate; DKK1; prostate cancer; WNT pathway

Indexed keywords

DICKKOPF 1 PROTEIN; IBANDRONIC ACID; RECEPTOR; WNT5A PROTEIN; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

AGED; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; DIPHOSPHONATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WNT PROTEINS; WNT1 PROTEIN;

EID: 79954461450     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23070     Document Type: Article

References (30)

1. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P,. 2000. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954. (Pubitemid 30395820)
2. Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y,. 2008. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases. Int J Cancer 123: 1034-1042.
3. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ,. 2000. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 31: 578-583. (Pubitemid 30323983)
4. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA,. 2004. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications. Cancer 101: 1345-1356. (Pubitemid 39180390)
5. Clarke NW, McClure J, George NJ,. 1993. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 24: 286-290. (Pubitemid 23246064)
6. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G,. 2007. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13: 156-163.
7. Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, Tamada K, Oneyama C, Okada M, Takumi T, Nishita M, Minami Y,. 2009. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28: 3197-3208.
8. Fromigue O, Lagneaux L, Body JJ,. 2000. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211-2221.
9. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET,. 2005. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65: 7554-7560. (Pubitemid 41297224)
10. Hall CL, Kang S, MacDougald OA, Keller ET,. 2006. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97: 661-672.
11. Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET,. 2008. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 68: 1396-1404.
12. Iozzo RV, Eichstetter I, Danielson KG,. 1995. Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res 55: 3495-3499.
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. 2009. Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
14. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, Yasui W, Kikuchi A,. 2006. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 66: 10439-10448. (Pubitemid 44799765)
15. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, Hayward SW, Bhowmick NA,. 2008. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 27: 7118-7130.
16. Logothetis CJ, Lin SH,. 2005. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5: 21-28. (Pubitemid 40052322)
17. McDonald SL, Silver A,. 2009. The opposing roles of Wnt-5a in cancer. Br J Cancer 101: 209-214.
18. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR,. 2007. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25: 1038-1042. (Pubitemid 46596753)
19. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH,. 2006. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38: 617-627.
20. Pukrop T, Klemm F, Hagemann T, Gradl D, Schulz M, Siemes S, Trumper L, Binder C,. 2006. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci USA 103: 5454-5459.
21. Rentsch CA, Cecchini MG, Thalmann GN,. 2009. Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer. Swiss Med Wkly 139: 220-225.
22. Reya T, Clevers H,. 2005. Wnt signalling in stem cells and cancer. Nature 434: 843-850. (Pubitemid 40558990)
23. Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, Ferracini R,. 2008. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS ONE 3: e3627.
24. Saad F,. 2002. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 1: 145-1452.
25. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA,. 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105.
26. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N,. 2003. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008-2012. (Pubitemid 36576705)
27. Tang X, Zhang Q, Shi S, Yen Y, Li X, Zhang Y, Zhou K, Le AD,. 2010. Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer 126: 90-103.
28. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD, Jr., 2003. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494. (Pubitemid 38010074)
29. Verdijk R, Franke HR, Wolbers F, Vermes I,. 2007. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 246: 308-312. (Pubitemid 44959401)
30. Yamamoto H, Oue N, Sato A, Hasegawa Y, Yamamoto H, Matsubara A, Yasui W, Kikuchi A,. 2010. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 29: 2036-2046.